India, July 9 -- Stereotaxis Inc. (STXS), a surgical robotics company, on Thursday announced the acquisition of Robocath, an established robotics company for interventions in cardiology and neurointerventions.
The companies plan to pool resources in developing next-generation robotic solutions for electrophysiology, interventional cardiology, and endovascular procedures.
Stereotaxis previously announced the acquisition in April 2026 via a share sale agreement worth approximately $20 million in cash and common stock.
googletag.cmd.push(function() { googletag.display('div-gpt-ad-1568189509843-0'); });
With the agreement, the company also gains Robocath's proprietary R-One technology, which has shown a 98% technical procedure success with ...